Molbio Diagnostics opened its initial public offering for subscription on Aug. 10, 2024, on Indian stock exchanges [1, 2].
The offering marks a significant move for the diagnostics firm to scale its operations through public capital. This transition allows the company to diversify its funding sources while providing liquidity for early backers.
The company set the price band for the IPO at ₹768 to ₹807 per share [1]. At the upper end of this price range, the valuation of Molbio Diagnostics is approximately ₹9,300 crore [1]. The total size of the IPO is estimated at roughly ₹1,000 crore [1].
Financial records indicate the target amount to be raised through the offering is between ₹904 crore and ₹940 crore [2]. To build momentum before the public launch, the company secured ₹281.5 crore from anchor investors [2]. These anchor investors include Temasek and Motilal Oswal [1, 2].
The IPO comes as the company seeks to expand its footprint in the Indian healthcare market. By listing on the exchanges, Molbio Diagnostics joins a growing number of specialized medical technology firms seeking public investment to fund research and development, a critical component of the diagnostics sector.
“The valuation of Molbio Diagnostics is approximately ₹9,300 crore.”
The entry of Molbio Diagnostics into the public market reflects a broader trend of healthcare infrastructure investment in India. By securing significant backing from institutional players like Temasek, the company demonstrates strong confidence from global investors in the scalability of its diagnostic platforms. The successful raising of nearly ₹1,000 crore would provide the necessary capital to compete with larger global medical device firms.
